Clinical trials
System Lupus Erythematosus(SLE) clinical trials
Below are recruiting system lupus erythematosus(sle) clinical trials, each written for real people, not researchers. We’re tracking 223 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07102030Recruiting
Understanding lupus subgroups to improve treatment
This study is trying to better understand lupus (SLE) by looking at different types of the disease. It may help doctors find more personalized treatments in the future.
StockholmAges 18–100 - NCT03138941Recruiting
Checking if a lupus control definition fits Asia-Pacific patients
This study tests whether a specific lupus “low disease activity” target (called LLDAS) works the same way in people across the Asia-Pacific region. It may help doctors use clearer goals to track how well lupus is controlled.
Adelaide, South AustraliaAges 18 years+ - NCT06614270Recruiting
CAR-NK cell therapy for severe autoimmune diseases
This trial tests a new type of immune cell therapy using modified natural killer cells (CAR-NK) that target a protein called CD19 and produce helpful signals (IL-10 and IL-15). It is for people with certain autoimmune diseases that have not improved with standard treatments or have come back after getting better.
Hangzhou, ZhejiangAges 18–65 - NCT04833465Recruiting
Testing a new outcome measure in kids with rheumatology diseases
This study looks at how to measure treatment success in children with juvenile idiopathic arthritis (JIA), lupus (SLE), or fibromyalgia (FM). It may help doctors track symptoms more reliably over time.
Washington D.C., District of ColumbiaAges 5–21 - NCT06570798RecruitingPhase 2
Testing Two Drugs for Lupus and Rheumatoid Arthritis
This trial tests two study drugs, inebilizumab and blinatumomab, for people with lupus (SLE) or rheumatoid arthritis (RA) that hasn't gotten better with standard treatments. It focuses on those with active disease, especially lupus-related kidney problems.
Scottsdale, ArizonaAges 18–75 - NCT07180537Recruiting
Health course for joint and mood conditions
This study tests an online health course that helps improve diet and self-care to support cell health and wellbeing. It is for people with certain rheumatological conditions like rheumatoid arthritis, lupus, or psoriatic arthritis, who also have mood concerns.
Iowa City, IowaAges 18–100 - NCT04902807Recruiting
Tool to help decide diagnosis and treatment in immune disorders
This trial tests a tool (a way of collecting health information) to help doctors make better diagnosis, prognosis, and treatment decisions for children with certain immune problems. It also includes healthy children (like relatives) as comparison groups, to see how well the tool works.
ParisAges 1–18 - NCT06316791RecruitingEarly Phase 1
CNCT19 CAR-T therapy for refractory autoimmune diseases
This early-phase study tests a new CAR-T cell therapy (CNCT19) for people with certain autoimmune diseases that have not responded to standard treatments. It targets a protein called CD19 on immune cells to help reset the immune system and reduce disease activity.
Zhengzhou, HenanAges 18–70 - NCT06465147RecruitingPhase 1
Cell therapy for hard-to-treat lupus (REACT-01)
This trial tests a new type of cell therapy (CAR T-cells) to see if it can stop the immune system from attacking the body in severe lupus. It’s for people ages 2–30 whose lupus is not controlled by other treatments and who are willing to be treated at Seattle Children’s Hospital.
Seattle, WashingtonAges 2–30 - NCT06581562RecruitingPhase 1
Testing rituximab plus AB-101 for autoimmune diseases
This trial tests a new treatment (AB-101) combined with rituximab for people with certain autoimmune diseases like rheumatoid arthritis, pemphigus vulgaris, vasculitis, or lupus. It is for those who have not had success with standard therapies.
Plantation, FloridaAges 18 years+ - NCT06594068RecruitingPhase 4
Anifrolumab in breastfeeding mothers with lupus
This study is looking at how the lupus medicine anifrolumab passes into breast milk and affects mothers and their babies. It is for women who are already taking anifrolumab for lupus and are breastfeeding a baby born at 32 weeks or later.
Las Vegas, NevadaAges 18–130 - NCT06659029Recruiting
Study on pregnancy outcomes in lupus patients using anifrolumab
This study tracks the health of pregnant women with moderate to severe lupus who have been treated with anifrolumab, compared to those treated with other lupus medications. It aims to understand how these treatments affect both mother and baby.
Wilmington, North CarolinaAges Any age - NCT06778343Recruiting
Biomarkers study for inflammatory rheumatic diseases
This study is looking for people with ankylosing spondylitis, rheumatoid arthritis, or lupus to help find biomarkers that may make diagnosis easier. If you have one of these conditions and haven't tried biologic therapies, you may be able to join.
LisbonAges 18–65 - NCT06801119RecruitingPhase 1
HN2301 for autoimmune diseases study
This trial tests a new mRNA treatment called HN2301 for people with autoimmune diseases like lupus, scleroderma, or rheumatoid arthritis. It aims to see if the treatment is safe and helps control the disease.
Hefei, AnhuiAges 18–69 - NCT06934447RecruitingPhase 1
CAR-T cell therapy for hard-to-treat lupus in kids
This trial tests a new type of cell therapy, called BCMA/CD70 CAR-T, for children with lupus that hasn't improved with standard treatments. The goal is to see if it can safely reduce disease activity.
Hangzhou, ZhejiangAges 5 years+ - NCT07000110Recruiting
Anifrolumab and risk study for lupus patients
This study looks at potential risks of the lupus medication anifrolumab in people with moderate to severe SLE. It focuses on serious infections and malignancies to see how safe the treatment is.
CopenhagenAges 18–130 - NCT07049653Recruiting
Anifrolumab pregnancy safety study
This study looks at pregnancy outcomes in women with lupus (SLE) who were or were not treated with the drug anifrolumab. It helps understand if anifrolumab is safe to use during pregnancy.
Cary, North CarolinaAges 18–130 - NCT07352332Recruiting
Immune study of a new treatment for hard-to-treat lupus in children
This study looks at how a treatment called CD3xCD19 BiTE affects the immune system of children with lupus that hasn't gotten better with standard medicines. It uses leftover blood samples to learn more about why some children don't respond to usual treatments.
HangzhouAges 5 years+ - NCT07371468RecruitingPhase 1
Study of an experimental drug for lupus, rheumatoid arthritis, and related conditions
This trial tests a new drug called GSK5926371 for people with certain autoimmune diseases that affect the joints, skin, and other tissues. It aims to see if the drug is safe and how well it works.
Buenos AiresAges 18–70 - NCT02422875Enrolling by invitation
Study of immune markers in autoimmune disease and lupus
This study looks at blood and immune cell markers (autoantibodies and immune cell “signatures”) to better understand autoimmune conditions, including lupus. It may help researchers identify which markers are linked to disease and how immune cells respond after vaccination.
Atlanta, GeorgiaAges 18 years+ - NCT07305116RecruitingPhase 1
CAR T-cell therapy for autoimmune diseases
This trial tests a new immune therapy called CAR T-cells that target two proteins (CD19 and BCMA) to treat autoimmune diseases like lupus, nephrotic syndrome, and others. It is for people whose standard treatments have not worked well enough.
Hangzhou, ZhejiangAges 3 years+ - NCT07507201RecruitingEarly Phase 1
Car-T cells for autoimmune diseases like lupus
This trial tests whether specially-engineered immune cells (CAR-T cells) can help people with certain autoimmune diseases that haven't gotten better with standard treatments. The cells are designed to target and remove faulty B cells that are causing the immune system to attack the body.
Hangzhou, ZhejiangAges 3 years+ - NCT07586267RecruitingEarly Phase 1
CAR-T cell therapy for autoimmune blood diseases
This early-stage trial tests a new type of cell therapy (CAR-T cells) designed to treat severe autoimmune diseases where the immune system attacks the body's own organs. The therapy targets specific immune cells (B cells) that may be causing the disease. It may help patients who haven't improved with standard treatments or can't tolerate them.
Hangzhou, ZhejiangAges 3 years+ - NCT07440537RecruitingPhase 2
Testing ICP-488 for active cutaneous lupus (skin lupus)
This trial tests an experimental drug called ICP-488 for people with active cutaneous lupus erythematosus (CLE), a type of lupus that affects the skin. It aims to see if the drug can reduce skin inflammation and improve symptoms.
Hefei, AnhuiAges 18–75
Hear when a new System Lupus Erythematosus(SLE) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for system lupus erythematosus(sle)?
- Yes. Clin2 currently lists 223 recruiting system lupus erythematosus(sle) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a system lupus erythematosus(sle) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a system lupus erythematosus(sle) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.